Webinar: Using Peptide-Drug Conjugates (PDCs) for the Precise Treatment of Pulmonary Fibrosis

Join us as Dr. Kelly Bugatti, a postdoctoral researcher from the University of Parma, walks us through the innovative world of Peptide-Drug Conjugates.
Highlights of the Presentation -
· Targeted therapy represents an emerging paradigm for the current biomedical research, since selective delivery of drugs may be a good strategy to improve the therapeutic efficiency, to overcome drug resistance and to reduce the off-target effects.
· The focus of the webinar will be the Peptide-Drug Conjugates (PDCs), constructs composed by 1) a peptidic targeting unit; 2) the drug 3) a linker that connects these two portions.
· After a brief introduction about the rationale behind this technique, the synthesis of a panel of PDCs aiming at the precise treatment of pulmonary fibrosis will be shown.
· These PDCs were designed to selectively deliver nintedanib - a potent kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis - by means of a peptidomimetic targeting αVβ6 integrin - a receptor overexpressed in fibrotic tissues.
· Finally, the results of the in vitro biological evaluation will be presented, which were very promising and allowed us to start the in vivo evaluation of one of these PDCs.
#PeptideDrugConjugates #PDC #bioconjugation #conjugation #webinar